United Kingdom In-Vitro Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The United Kingdom In-vitro Diagnostics market is segmented by Technique (Clinical Chemistry, Molecular Diagnostics Immuno Diagnostics, Other Techniques), Product (Instrument, Reagent, Other Products), Usability (Disposable IVD Devices Reusable IVD Devices), Application (Infectious Disease, Diabetes, Cancer/Oncology, Cardiology and Other Applications) and End User (Diagnostics Laboratories, Hospitals and Clinics, Other End Users). The report offers the value (in USD million) for the above segments.

Market Snapshot

CAGR
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 7.81 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The United Kingdom In-vitro Diagnostics market was valued at USD 3,126.39 million in 2021 and is expected to reach USD 4984.98 million by 2027, registering a CAGR of 7.81% during the forecast period.

The emergence of the COVID-19 pandemic transformed the in vitro diagnostics market in the country, both an advancement perspective and awareness about it among the general public. It led to the high demand for in vitro diagnostics products for COVID-19 diagnosis and treatment.In the diagnosis and detection of COVID-19, in vitro diagnostics tests were majorly used even in the non-symptomatic patients in the United Kingdom. The two primary testing methods used in the detection of COVID-19 infection include the antibody test and the antigen test. These are types of in-vitro diagnostics tests. The launch of new and advanced products related to COVID-19 detection and diagnostics by the key market leaders along with some new companies further boosted the growth of the studied market of the in-vitro diagnostics market in the United Kingdom. For instance, in November 2020, Beckman Coulter, a company of Danaher Corporation, launched the SARS-CoV-2 Immunoglobulin M (IgM) assay in countries accepting the CE mark. Additionally, the launch of regulatory frameworks by the parliament related to the mandatory COVID-19 testing will further expand the growth opportunities in-vitro diagnostics market in the country. For instance, as per the news reports, to open its economy to the outer world, the United Kingdom government may launch free COVID-19 antibody tests, which deliver result in 20 minutes. The test is the finger prick test and developed by UK Rapid Test Consortium (UK-RTC) and was found to be 98.6% accurate in secret test trials.

The major factors fueling the market growth are the rising prevalence of chronic disease has increased the demand for early and effective diagnostic tests, an increasing use of point-of-care (POC) diagnostics and increasing awareness and acceptance of personalized medicine and companion diagnostics have also helped the market growth.

The rising prevalence of chronic diseases is a major factor driving the market growth. For instance, as per the July 2021 report of the British Heart Foundation, there were about 7.6 million people in the United Kingdom were living with heart and circulatory diseases, of which 4 million people were male, and 3.6 million were female. Also, the rising geriatric population of the country will have a positive outlook on the market, as it is more prone to diseases and other medical conditions. The Future of an Ageing Population report by the Government Office of Science estimated that by 2040, one in seven people of the country is projected to be aged over 75. Furthermore, diabetes is one of the most prevalent chronic diseases in the United Kingdom. As per the report of the Diabetes UK, published in February 2020, about, 3.9 million people in the United Kingdom were living with diagnosed diabetes in 2019, with 3.3 million people in the England region, and 90% of these people had type 2 diabetes.

The increasing investment in research and development, along with the launch of new and advanced products from key market leaders and government initiatives in the country, is expected to boost the growth of the market studied, during the forecast period. For instance, in May 2020, the United Kingom government signed a contract with Abbott Laboratories for the supply of laboratory-based IgG-antibody tests to the National Health Services in different parts of the country. Also, in March 2020, the United Kingdom government provided a funding of GBP 16 million to QuantuMDx for the development of a portable diagnostics system for SARS-CoV-2, and in July 2021, QuantuMDx announced the launch of a rapid polymerase chain reaction point-of-care diagnostic system, called Q-POC, for COVID-19.

However, stringent regulatory frameworks in the country is expected to impede the growth of the in-vitro diagnostics market in the United Kingdom.

Scope of the report

As per the scope of this report, in-vitro diagnostics involves medical devices and consumables that are utilized to perform in vitro tests on various biological samples. They are used for the diagnosis of various medical conditions, such as diabetes and cancer. The United Kingdom In-Vitro Diagnostics Market market is segmented by Technique (Clinical Chemistry, Molecular Diagnostics Immuno Diagnostics, Other Techniques), Product (Instrument, Reagent, Other Products), Usability (Disposable IVD Devices Reusable IVD Devices), Application (Infectious Disease, Diabetes, Cancer/Oncology, Cardiology and Other Applications) and End User (Diagnostics Laboratories, Hospitals and Clinics, Other End Users). The report offers the value (in USD million) for the above segments.

By Technique
Clinical Chemistry
Molecular Diagnostics
Immuno Diagnostics
Other Techniques
By Product
Instrument
Reagent
Other Products
By Usability
Disposable IVD Devices
Reusable IVD Devices
By Application
Infectious Disease
Diabetes
Cancer/Oncology
Cardiology
Other Applications
By End-Users
Diagnostic Laboratories
Hospitals and Clinics
Other End-Users

Report scope can be customized per your requirements. Click here.

Key Market Trends

Infectious Diseases Segment Holds the Major Share During the Forecast Period

By Application, the infectious diseases segment is expected to hold a significant market share. The infectious diseases include HIV/AIDS, tuberculosis, hepatitis B, hepatitis C, still posing a significant burden in the United Kingdom. Also, the impact of the COVID 19 pandemic positively impacted the segment’s growth. According to Public Health England Hepatitis C in the United Kingdom 2020, an estimated 118,000 people were chronically infected with hepatitis C (HCV) with many of them belonging to marginalized and underserved groups in society.

Moreover growing awareness regarding the early diagnosis and treatment, especially for infectious diseases in the country, is expected to contribute to market growth over the period. TB Alert is the United Kingdom’s national tuberculosis charity raising public and professional awareness about TB. TB Alert’s work in the United Kingdom focuses on making sure people with TB are diagnosed and treated as quickly as possible. Such initiatives in the country boosted diagnostics of the diseases, boosting the segment’s growth.

Hence, owing to the rising burden of infectious diseases, and the COVID-19 pandemic, along with the expansion of the international market, players are driving the market growth for in-vitro diagnostics for infectious diseases in the United Kingdom

Number of  Cancer Cases, United Kingdom, 2020

Competitive Landscape

United Kingdom is a developed region with well-structured healthcare system. As a result, many global players in the in-vitro diagnostics market are present in the country. Moreover, some domestic players have also been competing in the UK market. These factors have made the region very competitive. Abbott Laboratories announced the signing of a contract with the UK government for the supply of laboratory-based IgG-antibody tests to the National Health Services (NHS) in May 2020.

RECENT DEVELOPMENTS

  • In June 2021, Abbott Laboratories announced receiving the CE mark for its COVID-19 detection test called Panbio COVID-19 Antigen Self Test.
  • In June 2021, bioMerieux signed a distribution agreement with Specific Diagnostics for the distribution of antibody susceptivity test (AST) in Europe, called REVEAL Rapid AST test.
  • In July 2021, Bio-Rad Laboratories launched COVID-19 diagnostics assay kit in the European markets, Reliance SARS-CoV-2/FluA/FluB RT-PCR Kit (IVD).

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence of Chronic Diseases

      2. 4.2.2 Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics

      3. 4.2.3 Increasing Use of Point-of-care (POC) Diagnostics

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulations

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value- USD Million)

    1. 5.1 By Technique

      1. 5.1.1 Clinical Chemistry

      2. 5.1.2 Molecular Diagnostics

      3. 5.1.3 Immuno Diagnostics

      4. 5.1.4 Other Techniques

    2. 5.2 By Product

      1. 5.2.1 Instrument

      2. 5.2.2 Reagent

      3. 5.2.3 Other Products

    3. 5.3 By Usability

      1. 5.3.1 Disposable IVD Devices

      2. 5.3.2 Reusable IVD Devices

    4. 5.4 By Application

      1. 5.4.1 Infectious Disease

      2. 5.4.2 Diabetes

      3. 5.4.3 Cancer/Oncology

      4. 5.4.4 Cardiology

      5. 5.4.5 Other Applications

    5. 5.5 By End-Users

      1. 5.5.1 Diagnostic Laboratories

      2. 5.5.2 Hospitals and Clinics

      3. 5.5.3 Other End-Users

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Becton, Dickinson and Company

      3. 6.1.3 bioMerieux SA

      4. 6.1.4 Bio-Rad Laboratories, Inc.

      5. 6.1.5 Danaher Corporation

      6. 6.1.6 F. Hoffmann-La Roche AG

      7. 6.1.7 QIAGEN N.V.

      8. 6.1.8 Siemens Healthineers AG

      9. 6.1.9 Sysmex Corporation

      10. 6.1.10 Thermo Fischer Scientific Inc.

      11. 6.1.11 Fujifilm Holdings Corporation

      12. 6.1.12 Ortho Clinical Diagnostics

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The United Kingdom In-Vitro Diagnostics Market market is studied from 2019 - 2027.

The United Kingdom In-Vitro Diagnostics Market is growing at a CAGR of 7.81% over the next 5 years.

The United Kingdom In-Vitro Diagnostics Market is valued at 3126 Million USD in 2019.

The United Kingdom In-Vitro Diagnostics Market is valued at 4984 Million USD in 2027.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Thermo Fischer Scientific Inc., QIAGEN N.V., Abbott Laboratories, Siemens Healthcare GmbH, F. Hoffmann-La Roche AG are the major companies operating in United Kingdom In-Vitro Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!